South African antitrust authorities closed an investigation into Johnson & Johnson and its Janssen subsidiary for charging excessive prices for a tuberculosis drug. The companies agreed not to enforce a secondary patent on the drug, allowing generic companies to offer a cheaper version. They also reduced the price charged to the National Department of Health by 40%. The Competition Commission found the new price to be in line with what the companies offer to the Global Drug Facility, the largest procurer of tuberculosis medicines. As a result, the Commission decided not to pursue an anti-competitive complaint filed last September before a tribunal.
Source link
South Africa and J&J agree on wider access to tuberculosis treatment
